GlassScriptPhysician profile
Kate W Hocquard
NPI 1396184743
$545.27
in general payments reported to CMS, 2019-2025
12 companies · $71.58 in 2025
The $71.58 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.96 · 2020: $73.80 · 2021: $105 · 2022: $128 · 2023: $73.30 · 2024: $78.06 · 2025: $71.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $119.64 | 2022-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $100.75 | 2021-2024 | Vyepti |
| Novartis Pharmaceuticals Corporation | $74.55 | 2019-2022 | |
| Biogen, INC. | $70.43 | 2020-2025 | Tysabri |
| Amgen INC. | $45.19 | 2020-2021 | |
| Abbvie INC. | $37.71 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $24.58 | 2022-2023 | Ingrezza, Ongentys |
| Pfizer INC. | $17.62 | 2023 | |
| Ceribell, INC. | $17.27 | 2021 | |
| Genentech USA, INC. | $13.55 | 2023 | Ocrevus |
| Emd Serono, INC. | $12.75 | 2023 | Mavenclad |
| Mdd US Operations, LLC | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Hocquard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.